Webinar | Screen, Optimize, and Characterize Your Viral Vector Production with Confidence

Screen, Optimize, and Characterize Your Viral Vector Production With Confidence

Achieving high titers is difficult, and producers face challenges in cost and time. Even after the initial screening, there are still parameters that need to be optimized to define the design space.

Join our experts to learn some strategies that can enhance clinical-stage AAV and LV production.

What Will You Learn:

Screen and optimize your media, transfection reagents, and cell lines 
Optimize your Critical Process Parameters (CPPs) with scaled-down models 
Create your design space using Design of Experiment (DoE) methodology

Clear form data

Please Complete the Form

First Name *

Last Name *

E-Mail *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Watch Online

Sandra Klausing

Manager of Media and Process Development Xell

Sandra has more than 17 years of experience in biotechnology with an extensive background in cell culture technologies. She joined Xell in 2013 and later led its transition to becoming part of Sartorius.

In her role as Manager of Media and Process Development, she focuses on cell culture media and processes for gene therapy applications, specifically AAV and lentiviral vector production.

David Ede

Process Technology Manager – Viral-based Therapeutics

David is a biomedical and chemical engineer. He has degrees from the University of Utah and Oklahoma State University, United States, and has a background in process development and manufacturing for viral vectors.

In his current role as Process Technology Manager at Sartorius, David supports viral-based biotechnology stakeholders and helps bring their bioprocess from R&D to commercial scale.